Results 111 to 120 of about 63,667 (225)

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

International Journal of Cancer, Volume 158, Issue 9, Page 2298-2308, 1 May 2026.
What's new? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar, Paula Lakrout, Valérie Potard, Aurélien Belot, Jacques Cadranel, Christine Jacomet, Christine Katlama, Esaïe Marshall, Olivier Lambotte, Romain Palich, Sylvie Ronot‐Bregigeon, Jean‐Philippe Spano, Anne‐Marie Bouvier, Alain Makinson, Dominique Costagliola   +14 more
wiley   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

Evaluation of Relative Bioavailability and Food Effect of a Fixed‐Dose Combination Tablet of Islatravir and Lenacapavir

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Long‐acting oral HIV‐1 treatments can potentially reduce pill burden, treatment fatigue, suboptimal adherence, and treatment failure. A combination of islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a capsid inhibitor, is being investigated as a weekly oral HIV‐1 treatment.
Jing Niu, Haeyoung Zhang, John Ling, Sharline Madera, Nerissa Kwok, Steve West, Diane Longo, Gillian Gillespie, Cyril Llamoso, Dhananjay D. Marathe   +9 more
wiley   +1 more source

Defining HIV Pre‐Exposure Prophylaxis (PrEP) Persistence: A Scoping Review

Journal of the International AIDS Society, Volume 29, Issue 5, May 2026.
ABSTRACT Introduction When assessing the effectiveness of pre‐exposure prophylaxis (PrEP) programmes, interventions, or modalities, it is important to understand patterns of PrEP use. Continued use of PrEP is frequently referred to as PrEP “persistence.” But persistence is not defined consistently, and differences impact the interpretation of study ...
Sarah E. Rutstein, Grace E. Mulholland, Laura Limarzi‐Klyn, Annabelle Gallinek, Nicole Brown, William C. Miller   +5 more
wiley   +1 more source

The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. [PDF]

, 2020
BACKGROUND:Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective.
Barnhart, Scott, Gilmore, Hailey J, Grignon, Jessica S, Hunt, Gillian, Liegler, Teri, Lippman, Sheri A, Mooney, Alyssa C, Prach, Lisa M, Puren, Adrian, Truong, Hong-Ha M   +9 more
core  

Long‐Acting PrEP for People With High Vulnerability to HIV Acquisition in Brazil: A Cost‐Effectiveness Analysis

Journal of the International AIDS Society, Volume 29, Issue 5, May 2026.
ABSTRACT Introduction In Brazil, men who have sex with men (MSM) and transgender women (TGW) remain heavily affected by HIV. Long‐acting pre‐exposure prophylaxis (LA PrEP) with injectable cabotegravir (CAB‐LA) or lenacapavir (LEN‐LA) is more effective at preventing HIV acquisition than oral PrEP.
Wanyi Chen, Paula M. Luz, Anjali Srinivasan, Beatriz Grinsztejn, Justine A. Scott, Anne M. Neilan, Valdiléa G. Veloso, Caitlin M. Dugdale, Kenneth A. Freedberg   +8 more
wiley   +1 more source

KSHV Genome in Saliva, Whole Blood and Kaposi's Sarcoma Biopsy Specimens in Republic of Congo: Phylogenetic Analysis and an APOBEC3B Mutational Signature

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Kaposi's sarcoma‐associated herpesvirus (KSHV) has been associated with a variety of diseases and is endemic in Sub‐Saharan Africa. We performed KSHV‐whole‐genome analysis and search for APOBEC‐editing to describe genetic diversity in samples issued from an endemic region.
Gervillien Arnold Malonga, Valentin Leducq, Antoine Fauchois, Dimitry Moudiongui Mboungou Malanda, Patrina Joseph Iloukou Mayakia, Juthèce Private Malanda‐Kiminou, Ferdinand Emaniel Brel Got, Fabien Gaël Mouamba, Vincent Calvez, Jean Felix Peko, Anne‑Geneviève Marcelin, Aude Jary   +11 more
wiley   +1 more source

Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response.
Qiumin Luo, Ruixuan Xu, Yeqiong Zhang, Wenxiong Xu, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng   +12 more
wiley   +1 more source

Renal Tubular Acidosis and Osteomalacia, Possibly Associated with Tenofovir

Turkish Journal of Nephrology, 2019
Tenofovir is one of the first-line new generation antiviral agents commonly used in chronic hepatitis B treatment. While being considered an effective and safe treatment, the most important side effect known is nephrotoxicity.
Faruk ELYİĞİT, Bengü ERKUL, Hakan YARKICI, Handan ARLI, Lütfiye Bilge ÇALIŞKAN, Harun AKAR   +5 more
doaj  

Discovery of 4‐Quinazolinone‐Containing Phenylalanine Derivatives as Potent, Resistant‐Tolerant HIV Capsid Inhibitors

MedComm, Volume 7, Issue 5, May 2026.
Novel phenylalanine derivatives were identified as HIV‐1 capsid inhibitors. IC‐2i showed significant anti‐HIV‐1 activity at picomolar concentrations. ABSTRACT The HIV‐1 capsid (CA) is a validated antiviral target that plays critical roles in both the early and late stages of the viral life cycle.
Xujie Zhang, Lin Sun, Laura Walsham, Yuexi Ma, Dang Ding, Mei Wang, Fabao Zhao, Jian Zhang, Zhao Wang, Shujing Xu, Xiangyi Jiang, Yang Zhou, Erik De Clercq, Christophe Pannecouque, Chin‐Ho Chen, David C. Goldstone, Xinyong Liu, Alexej Dick, Peng Zhan   +18 more
wiley   +1 more source